Close on the heels of receiving emergency use authorization for its COVID-19 vaccine Corbevax from India’s Drug Controller General, Biologics has announced plans to ramp up production.
The vaccine maker said it plans to complete production of the vaccine at a rate of 75 million doses per month and expects to touch more than 100 million doses per month by February.
“This capacity will enable the delivery of 30 crore doses as promised to the Government of India,” the Hyderabad-based company said in a release on Tuesday. However, it was not specified when the vaccine would become part of the national immunization program nor the cost of a single dose.
Biological E said the vaccine also plans to soon deliver more than one billion additional doses globally, developed in collaboration with the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine (Baylor) Houston, Texas . ,
India’s first indigenously developed protein sub-unit COVID-19 vaccine, a “recombinant protein sub-unit” vaccine developed from a component of the spike protein on the surface of the Corbevax virus, helps the body build an immune response against the virus. helps.
Managing Director Mahima Datla said, “Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. As our background, we have developed an affordable and effective COVID-19 vaccine. It has become a reality now.”
Thanking Prime Minister Narendra Modi for making immunization a national mission, he said, “His vision and the advance commitments we have received towards Corbevax have been instrumental in our ability to build and build on such a huge potential.” Huh.”
He said the vaccine would be effective in both scale and affordability, providing sustainable access to low- and middle-income countries.
Biologicals E said it has completed two Phase III clinical trials for Corbevax involving more than 3,000 subjects aged 18-80 at 33 study sites across India. The vaccine was found to be safe, well tolerated and immunogenic.